Navigating Treatment Choices and Financial Considerations in BCG-Unresponsive NMIBC
February 11th 2025A panelist discusses how less frequent treatment administration schedules and simpler delivery requirements of newer gene therapies reduce clinic resource burden by minimizing staff time, equipment usage, and biosafety requirements, allowing for more efficient allocation of health care resources.
BCG-Unresponsive NMIBC: Balancing Care and Financial Considerations
February 11th 2025A panelist discusses how treatment decisions for BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) involve careful consideration of patient preferences, long-term cost-effectiveness, and available financial assistance programs, balancing the higher upfront costs of newer therapies with their potential economic benefits from reduced recurrence rates and treatment frequency.
The Impact of Gene Therapy and Advancements in BCG-Unresponsive NMIBC Treatment
February 4th 2025A panelist discusses how targeted gene therapy has revolutionized BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) treatment through agents like nadofaragene firadenovec, which shows promising complete response rates at 3 months, though long-term follow-up remains crucial for assessing durability of response and comparing real-world outcomes with clinical trial data.
Navigating BCG-Unresponsive NMIBC and Emerging Therapies
February 4th 2025A panelist discusses how BCG-unresponsive non–muscle-invasive bladder cancer (NMIBC) has evolved from having limited treatment options beyond radical cystectomy to now having several therapeutic alternatives including intravesical chemotherapy and immunotherapy, though each current option comes with its own efficacy limitations and adverse effect profiles that must be carefully weighed against patient factors.